Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 22 clinical trials
Non-vitamin K Antagonist Oral Anticoagulants in Patients With Atrial High Rate Episodes (NOAH)

NOAC edoxaban is superior to current therapy to pre-vent stroke, systemic embolism, or cardiovascular death in patients with AHRE and at least two stroke risk factors but without AF. The trial will be

  • 0 views
  • 15 Jun, 2022
  • 17 locations
Hamburg Edoxaban for Anticoagulation in COVID-19 Study (HERO-19)

Hero-19 aims to evaluate if an intensive anticoagulation strategy using Edoxaban on top of standard of care (SOC) of COVID-19 therapy is superior to SOC (in-hospital moderate anticoagulation

  • 4 views
  • 23 May, 2022
  • 10 locations
Population Pharmacokinetics of Edoxaban in Chinese Patients With Non-Valvular Atrial Fibrillation

Based on the population pharmacokinetic data of Chinese patients with atrial fibrillation, the study will evaluate the suitability of the ENGAGE Population Pharmacokinetics model of edoxaban in

  • 0 views
  • 02 Jul, 2022
  • 1 location
DOT HeartMate 3 Study

A prospective, single-center, randomized controlled trial of the feasibility and safety of apixaban in HeartMate 3 patients.

  • 0 views
  • 21 Apr, 2022
  • 1 location
Edoxaban Versus Edoxaban With antiPlatelet Agent In Patients With Atrial Fibrillation and Chronic Stable Coronary Artery Disease (EPIC-CAD)

This study evaluates the efficacy and safety of Edoxaban with the combination of edoxaban and antiplatelet in patients with stable CAD (coronary artery stenosis ≥50% on medical treatment or

percutaneous coronary intervention
atrial fibrillation
acute coronary syndrome
vascular disease
fibrillation
  • 51 views
  • 09 Jul, 2022
  • 12 locations
EdoxabaN foR IntraCranial Hemorrhage Survivors With Atrial Fibrillation (ENRICH-AF) (ENRICH-AF)

To assess whether edoxaban (60/30 mg daily) compared to non-antithrombotic medical therapy (either no antithrombotic therapy or antiplatelet monotherapy) reduces the risk of stroke (composite of

anticoagulants
stroke
atrial fibrillation
edoxaban
vascular disease
  • 15 views
  • 16 Feb, 2022
  • 140 locations
Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABG (PACES)

The primary objective of this study is to evaluate the effectiveness (prevention of thromboembolic events) and safety (major bleeding) of adding oral anticoagulation (OAC) to background antiplatelet therapy in patients who develop new-onset post-operative atrial fibrillation (POAF) after isolated coronary artery bypass graft (CABG) surgery. All patients with a qualifying …

atrial fibrillation
fibrillation
apixaban
clopidogrel
aspirin
  • 112 views
  • 22 Sep, 2022
  • 45 locations
Effects of Edoxaban on Platelet Aggregation

: Analyze the role of edoxaban on platelet aggregation in SCAD patients. Methods and Results: This is a prospective, non-randomized, interventional study of SCAD patients taking low-dose

anticoagulants
coronary artery bypass graft
stroke
antiplatelet therapy
clopidogrel
  • 0 views
  • 22 Nov, 2021
  • 1 location
Resolution of Thrombi in Left Atrial Appendage With Edoxaban

the efficacy of NOACs in resolving LAA thrombi available. Edoxaban, which has data showing efficacy and safety in thromboprophylaxis, can be the new option for treatment of patients with AF

anticoagulants
stroke
edoxaban
fibrillation
anticoagulation therapy
  • 0 views
  • 25 Jan, 2021
  • 11 locations
STroke Secondary Prevention With Catheter ABLation and EDoxaban for Patients With Non-valvular Atrial Fibrillation: STABLED Study

Catheter ablation (CA) has been reported to reduce risk of stroke in patients with nonvalvular atrial fibrillation (NVAF) in retrospective studies, but risk and benefit of CA has not been well elucidated in NVAF with recent cerebral infarction in prospective randomized trials.

  • 0 views
  • 22 Jan, 2021
  • 21 locations